Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03040674 · ClinicalTrials.gov registry record
An Observational Outcomes Study for Autologous Cell Therapy Among Patients With COPD and Interstitial Lung Disease
A clinical trial, sponsored by Lung Institute.
- Completed
- Registry status
- 489
- Enrollment target
NCT03040674 is a clinical trial that has completed, run by Lung Institute. The registered enrollment target is 489 participants.
The verdict
NCT03040674 has completed, sponsored by Lung Institute.
- COMPLETED
- Registry status
- 489 participants
- Enrollment target
Study Summary
The purpose of the Lung Institute is to collect and isolate a patient's own cells and platelet rich plasma (PRP) and deliver the product back to the patient same-day. Lung Institute's treatment is limited to self- funded patients with chronic lung disease - chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD). The patient's cells and platelet rich plasma are collected through venous harvesting. The hypothesized outcomes of Lung Institute therapy are safety and minimization of adverse events, a perceived improvement in the patient's lung condition (to be determined by their ability to be more physically active; walking greater distances with or without oxygen and improved quality of life scales), an improvement in the FEV1 among COPD patients, the ability to reduce their use of oxygen and possibly to stop it., the ability to function well without the use of rescue inhalers, reduction or ceasing of secondary pulmonary infections, reduction in emergency room visits and exacerbations related to their disease.
Interventions
- PROCEDURE Cell therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 489 participants |
| Start Date | 2017-01-03 |
| Est. Completion | 2020-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03040674
The ClinicalTrials.gov registry entry for NCT03040674 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 489 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lung Institute, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cell therapy is the first listed.
NCT03040674 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03040674 about?
NCT03040674 is a clinical study titled "An Observational Outcomes Study for Autologous Cell Therapy Among Patients With COPD and Interstitial Lung Disease". The purpose of the Lung Institute is to collect and isolate a patient's own cells and platelet rich plasma (PRP) and deliver the product back to the patient same-day. Lung Institute's treatment is limited to self- funded patients with chronic lung disease - chronic obstructive pulmonary disease (COP...
What is the current status of trial NCT03040674?
This trial is currently completed. The enrollment target is 489 participants. The study started on 2017-01-03. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT03040674?
The interventions under investigation include: Cell therapy (PROCEDURE).
Who is sponsoring clinical trial NCT03040674?
This trial is sponsored by Lung Institute, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.